CytomX outlines registrational trial plans for Varseta-M in third-line colorectal cancer with initial study start in 2027
CytomX Therapeutics, Inc. · PHARMACEUTICAL PREPARATIONS · Now $3.45
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS